Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 06, 2006. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of shareholding changes rather than a financial performance report.
Material Changes
The filing details a change in the number of Ordinary Share American Depositary Receipts (ADRs) held by the GlaxoSmithKline US Retirement Savings Plan ("the Plan").
- Date of Movement: February 02, 2006
- Previous Holding: 18,046,998 ADRs
- New Holding: 17,865,419 ADRs
- Average Price: $52.16
- Reason: A movement in the fund.
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, outlook, or specific risk factors. It notes that the Plan is a discretionary fund for current and former employees. Two directors, Dr. J P Garnier and Dr. T Yamada, are potentially interested in the shares held in the fund in the same capacity as other employees. The notification complies with Disclosure Rule 3.1.4R (1) (b).
Key Facts for Investor Verification
- Verify the impact of the fund movement on the total share count held by the GlaxoSmithKline US Retirement Savings Plan.
- Confirm the potential interest of Directors Dr. J P Garnier and Dr. T Yamada in the fund's holdings.
- Note that this filing does not reflect operational or financial performance metrics for the company.